Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 24

1.

Strain-Dependent Impact of G and SH Deletions Provide New Insights for Live-Attenuated HMPV Vaccine Development.

Dubois J, Pizzorno A, Cavanagh MH, Padey B, Nicolas de Lamballerie C, Uyar O, Venable MC, Carbonneau J, Traversier A, Julien T, Lavigne S, Couture C, Lina B, Hamelin MÈ, Terrier O, Rosa-Calatrava M, Boivin G.

Vaccines (Basel). 2019 Oct 30;7(4). pii: E164. doi: 10.3390/vaccines7040164.

2.

Novel calixarene-based surfactant enables low dose split inactivated vaccine protection against influenza infection.

Mandon ED, Pizzorno A, Traversier A, Champagne A, Hamelin ME, Lina B, Boivin G, Dejean E, Rosa-Calatrava M, Jawhari A.

Vaccine. 2020 Jan 10;38(2):278-287. doi: 10.1016/j.vaccine.2019.10.018. Epub 2019 Oct 18.

PMID:
31630939
3.

Characterization of cellular transcriptomic signatures induced by different respiratory viruses in human reconstituted airway epithelia.

Nicolas de Lamballerie C, Pizzorno A, Dubois J, Julien T, Padey B, Bouveret M, Traversier A, Legras-Lachuer C, Lina B, Boivin G, Terrier O, Rosa-Calatrava M.

Sci Rep. 2019 Aug 7;9(1):11493. doi: 10.1038/s41598-019-48013-7.

4.

Toll-like receptor 5 agonist flagellin reduces influenza A virus replication independently of type I interferon and interleukin 22 and improves antiviral efficacy of oseltamivir.

Georgel AF, Cayet D, Pizzorno A, Rosa-Calatrava M, Paget C, Sencio V, Dubuisson J, Trottein F, Sirard JC, Carnoy C.

Antiviral Res. 2019 Aug;168:28-35. doi: 10.1016/j.antiviral.2019.05.002. Epub 2019 May 9.

5.

Human metapneumovirus activates NOD-like receptor protein 3 inflammasome via its small hydrophobic protein which plays a detrimental role during infection in mice.

Lê VB, Dubois J, Couture C, Cavanagh MH, Uyar O, Pizzorno A, Rosa-Calatrava M, Hamelin MÈ, Boivin G.

PLoS Pathog. 2019 Apr 9;15(4):e1007689. doi: 10.1371/journal.ppat.1007689. eCollection 2019 Apr.

6.

Drug Repurposing Approaches for the Treatment of Influenza Viral Infection: Reviving Old Drugs to Fight Against a Long-Lived Enemy.

Pizzorno A, Padey B, Terrier O, Rosa-Calatrava M.

Front Immunol. 2019 Mar 19;10:531. doi: 10.3389/fimmu.2019.00531. eCollection 2019. Review.

7.

Repurposing of Drugs as Novel Influenza Inhibitors From Clinical Gene Expression Infection Signatures.

Pizzorno A, Terrier O, Nicolas de Lamballerie C, Julien T, Padey B, Traversier A, Roche M, Hamelin ME, Rhéaume C, Croze S, Escuret V, Poissy J, Lina B, Legras-Lachuer C, Textoris J, Boivin G, Rosa-Calatrava M.

Front Immunol. 2019 Jan 29;10:60. doi: 10.3389/fimmu.2019.00060. eCollection 2019.

8.

OVX836 a recombinant nucleoprotein vaccine inducing cellular responses and protective efficacy against multiple influenza A subtypes.

Del Campo J, Pizzorno A, Djebali S, Bouley J, Haller M, Pérez-Vargas J, Lina B, Boivin G, Hamelin ME, Nicolas F, Le Vert A, Leverrier Y, Rosa-Calatrava M, Marvel J, Hill F.

NPJ Vaccines. 2019 Jan 23;4:4. doi: 10.1038/s41541-019-0098-4. eCollection 2019.

9.

Role of p53/NF-κB functional balance in respiratory syncytial virus-induced inflammation response.

Machado D, Pizzorno A, Hoffmann J, Traversier A, Endtz H, Lina B, Rosa-Calatrava M, Paranhos-Baccala G, Terrier O.

J Gen Virol. 2018 Apr;99(4):489-500. doi: 10.1099/jgv.0.001040. Epub 2018 Mar 5.

PMID:
29504924
10.

Influenza A viruses alter the stability and antiviral contribution of host E3-ubiquitin ligase Mdm2 during the time-course of infection.

Pizzorno A, Dubois J, Machado D, Cartet G, Traversier A, Julien T, Lina B, Bourdon JC, Rosa-Calatrava M, Terrier O.

Sci Rep. 2018 Feb 27;8(1):3746. doi: 10.1038/s41598-018-22139-6.

11.

The combination of oseltamivir with azithromycin does not show additional benefits over oseltamivir monotherapy in mice infected with influenza A(H1N1)pdm2009 virus.

Fage C, Pizzorno A, Rhéaume C, Abed Y, Boivin G.

J Med Virol. 2017 Dec;89(12):2239-2243. doi: 10.1002/jmv.24911. Epub 2017 Aug 25.

PMID:
28792077
12.

The E119D neuraminidase mutation identified in a multidrug-resistant influenza A(H1N1)pdm09 isolate severely alters viral fitness in vitro and in animal models.

Abed Y, Bouhy X, L'Huillier AG, Rhéaume C, Pizzorno A, Retamal M, Fage C, Dubé K, Joly MH, Beaulieu E, Mallett C, Kaiser L, Boivin G.

Antiviral Res. 2016 Aug;132:6-12. doi: 10.1016/j.antiviral.2016.05.006. Epub 2016 May 13.

PMID:
27185624
13.

Permissive changes in the neuraminidase play a dominant role in improving the viral fitness of oseltamivir-resistant seasonal influenza A(H1N1) strains.

Abed Y, Pizzorno A, Bouhy X, Boivin G.

Antiviral Res. 2015 Feb;114:57-61. doi: 10.1016/j.antiviral.2014.12.006. Epub 2014 Dec 12.

PMID:
25512229
14.

Evolution of oseltamivir resistance mutations in Influenza A(H1N1) and A(H3N2) viruses during selection in experimentally infected mice.

Pizzorno A, Abed Y, Plante PL, Carbonneau J, Baz M, Hamelin MÈ, Corbeil J, Boivin G.

Antimicrob Agents Chemother. 2014 Nov;58(11):6398-405. doi: 10.1128/AAC.02956-14. Epub 2014 Aug 11.

15.

Oseltamivir-zanamivir combination therapy is not superior to zanamivir monotherapy in mice infected with influenza A(H3N2) and A(H1N1)pdm09 viruses.

Pizzorno A, Abed Y, Rhéaume C, Boivin G.

Antiviral Res. 2014 May;105:54-8. doi: 10.1016/j.antiviral.2014.02.017. Epub 2014 Feb 28.

PMID:
24583158
16.

Impact of potential permissive neuraminidase mutations on viral fitness of the H275Y oseltamivir-resistant influenza A(H1N1)pdm09 virus in vitro, in mice and in ferrets.

Abed Y, Pizzorno A, Bouhy X, Rhéaume C, Boivin G.

J Virol. 2014 Feb;88(3):1652-8. doi: 10.1128/JVI.02681-13. Epub 2013 Nov 20.

17.

Influenza virus resistance to neuraminidase inhibitors.

Samson M, Pizzorno A, Abed Y, Boivin G.

Antiviral Res. 2013 May;98(2):174-85. doi: 10.1016/j.antiviral.2013.03.014. Epub 2013 Mar 22. Review.

PMID:
23523943
18.

Evaluation of recombinant 2009 pandemic influenza A (H1N1) viruses harboring zanamivir resistance mutations in mice and ferrets.

Pizzorno A, Abed Y, Rhéaume C, Bouhy X, Boivin G.

Antimicrob Agents Chemother. 2013 Apr;57(4):1784-9. doi: 10.1128/AAC.02269-12. Epub 2013 Jan 28.

19.

Therapeutic activity of intramuscular peramivir in mice infected with a recombinant influenza A/WSN/33 (H1N1) virus containing the H275Y neuraminidase mutation.

Abed Y, Pizzorno A, Boivin G.

Antimicrob Agents Chemother. 2012 Aug;56(8):4375-80. doi: 10.1128/AAC.00753-12. Epub 2012 Jun 4.

20.

Impact of mutations at residue I223 of the neuraminidase protein on the resistance profile, replication level, and virulence of the 2009 pandemic influenza virus.

Pizzorno A, Abed Y, Bouhy X, Beaulieu E, Mallett C, Russell R, Boivin G.

Antimicrob Agents Chemother. 2012 Mar;56(3):1208-14. doi: 10.1128/AAC.05994-11. Epub 2011 Dec 27.

Supplemental Content

Loading ...
Support Center